Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749201 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ANOTUMLMNA | |
| SCHEMBL6749236 | 0.78 | ALDH1A1 (0.41) | MAPTTSHRNPSR1ALDH1A1KMT2A | |
| SCHEMBL6749056 | 0.77 | CA12 (0.38) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL7140092 | 0.76 | MTNR1A (0.39) | — | |
| SCHEMBL6747496 | 0.75 | TP53 (0.33) | NPSR1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL13722157 | 0.70 | MAPT (0.66) | MAPTTSHRNPSR1ALDH1A1MEN1 | |
| SCHEMBL6420673 | 0.70 | NOTUM (0.61) | MAPTNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL18974747 | 0.68 | CES1 (0.59) | MAPTALDH1A1KMT2AALDH3A1ALDH2 | |
| SCHEMBL29564490 | 0.68 | NOTUM (0.52) | NPSR1MEN1KMT2ANOTUM | |
| SCHEMBL9798486 | 0.67 | HPGD (0.63) | MAPTTSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | MAPT 1257/4885TSHR 3062/4885NPSR1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.